by Truveta staff | Jul 2, 2024 | Research
Citation Wang X, Xu Y, Norman G, et al. CGM Use in People with Type 2 Diabetes Initiating GLP-1 or GIP/GLP-1RA Therapy—Real-World Data. Diabetes. June 14, 2024. https://doi.org/10.2337/db24-1922-LB Recently, researchers published new insights in Diabetes exploring the...
by Truveta staff | Jun 17, 2024 | Data, News, Technology
Truveta now offers regulatory and audit capabilities to support our customers for real-world evidence (RWE) submissions to the Food and Drug Administration (FDA) and other global regulatory authority decisions. These regulatory grade capabilities advance Truveta’s...
by Truveta staff | May 28, 2024 | Research
Overall prescribing rates (GLP-1 RA prescriptions per total prescriptions) increased throughout the first quarter of 2024 (+20.9% increase in March 2024 compared to December 2023). First-time prescribing rates (first-time GLP-1 RA prescriptions per total...
by Truveta Research | May 22, 2024 | Research
Norovirus and rotavirus are significant contributors to gastrointestinal infections worldwide, creating risk for patient populations and strain on the healthcare system. Truveta Research evaluated trends in norovirus- and rotavirus-associated hospitalizations overall...
by Truveta staff | May 14, 2024 | News
Truveta Research and collaborators Anupam B. Jena, MD, PhD and Christopher Worsham, MD, MPH received the ISPOR 2024 Best General Poster Research Presentation Award for their poster presentation, HSD72: Baseline A1C and BMI Trends for People with Type 2 Diabetes...
